Avadel wins FDA approval for narcolepsy drug Lumryz
Avadel wins FDA approval for narcolepsy drug Lumryz in children
The expanded approval intensifies the rivalry with Jazz Pharmaceuticals, which has previously attempted to block Lumryz’s path to market.
Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug Lumryz
Avadel Pharmaceuticals plc AVDL announced that the FDA has approved its supplemental new drug application (sNDA) seeking label expansion of Lumryz. The drug is now approved in the United States for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven years and older with narcolepsy.
FDA OKs Once-Nightly Lumryz for Children with Narcolepsy
Lumryz is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness in children as young as 7 years with narcolepsy.
Avadel's narcolepsy drug Lumryz gets USFDA approval for pediatric use
Avadel's drug contains a central nervous system depressant drug called sodium oxybate, which helps increase the amount of time someone spends in deep sleep.
Avadel Gets Expanded FDA OK of Lumryz for Use in Children
Avadel Pharmaceuticals has won expanded Food and Drug Administration approval of its narcolepsy drug Lumryz for use in children. Avadel on Thursday said the FDA nod covers Lumryz for the treatment of cataplexy, or excessive daytime sleepiness, in children ages seven and older with narcolepsy, a chronic sleep disorder.
Avadel Pharma's SNDA For Lumryz Gets FDA Approval
Biopharmaceutical company Avadel Pharmaceuticals plc (AVDL), Thursday announced that the U.S. Food and Drug Administration (FDA) has
US FDA expands use of Avadel's sleep disorder drug to ages 7 and up
The U.S. Food and Drug Administration has approved Avadel Pharmaceuticals' sleep disorder drug for children aged 7 years and older, broadening its use and heating up competition for popular treatments from Jazz Pharmaceuticals.
Narcolepsy Market to Reach US$ 4.68 Billion by 2031, Rising at a CAGR of 9.3%, Report by CoherentMI
The narcolepsy market is undergoing significant changes as new treatment strategies and product innovations emerge. Our newly ...
Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook
Shares of Jazz Pharmaceuticals are trading only slightly higher in the last few weeks despite two unexpected wins. Explore ...
Newstalk11d
'I'd no control over it at all' - What it's like living with narcolepsy
Sharron McSherry was just 14 when she kept falling asleep in school - it wasn't until many years later that she was diagnosed ...
clinicaladvisor.com18h
Lumryz Approval Expanded to Include Pediatric Narcolepsy
Lumryz is an extended-release formulation of sodium oxybate, a central nervous system (CNS) depressant. Its therapeutic effects are believed to be mediated through GABA B actions at noradrenergic and ...
New York Magazine1mon
How I Sleep: The Narcoleptic Napping in Her Prius
A series about how people with highly specific sleeping situations fall asleep and stay asleep — and the products they use. Dawn Super frequently naps in her car. She was diagnosed with ...
RS-NEWS12d
How Medication Plays a Vital Role in Narcolepsy Symptom Management
Narcolepsy is a chronic neurological disorder that disrupts the brain’s ability to regulate sleep-wake cycles, often leading ...